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“Without knowledge action is useless, and
action without knowledge is futile”
Abu Bakr, 547 CE
This series of publications “Understanding
the Ontogeny of the Immune System to Pro-
mote Immune-Mediated Health for Life” in
Frontiers in Immunology provides a timely
summary of the many recent advances in
knowledge regarding the immune response
of the mother, fetus, newborn, and young
infant. This basic information provides the
foundation from which new approaches
to foster a smooth transition from the
relatively insular and protected in utero
environment – where bidirectional tol-
erance between mother and fetus is the
over-arching goal – to the postnatal envi-
ronment – where tolerance to self and
the acquired microbiota must be balanced
against the threat of pathogen invasion. But
to truly address the theme inherent in the
title of the Immunotherapies and Vaccines
section of Frontiers in which these publica-
tions appear, knowledge is only the begin-
ning. As Abu Bakr implied, the far greater
(and more important) challenge is for
immunologists to bridge between the sepa-
rate siloes in which they and vaccinologists
traditionally operate, then together to work
effectively with microbiologists, systems,
computational and structural biologists,
bioengineers, and formulation chemists to
translate emerging biological knowledge
into new products and solutions to fur-
ther reduce the global burden of infectious
diseases.
Although there has been a gratifying
49% decrease since 1990 in global mor-
tality under the age of 5 years to a rate
of ~6.3 million/year in 2013, the rate
remains too high; moreover, the rate of
decline in neonatal mortality has been
less (40%), with the result that 45%
of all under five mortality now occurs
in the first month of life (http://data.
unicef.org/child-mortality/). Collectively,
preterm birth and infection are believed
to account for approximately one-third
and 20% of these neonatal deaths, respec-
tively, with a fraction of preterm birth itself
related to infection. These numbers indi-
cate the remaining unmet need to more
effectively and efficiently apply existing
vaccines and to develop new vaccines to
further reduce the burden of infectious
diseases in early life.
Active immunization of infants and
young children – along with improvements
in hygiene and nutrition – appears to have
been an important factor in this reduc-
tion in under-five mortality. And while
extending these benefits of vaccines more
broadly throughout the world and develop-
ing new vaccines against major pathogens
for which effective vaccines are not yet
available are clear priorities going for-
ward, this Opinion will focus on knowl-
edge gaps in two areas, which if addressed
could inform approaches by which to fur-
ther reduce under-five mortality through
immunization. The first need is to bet-
ter define the heterologous effects of vac-
cines and vaccine schedules in humans
and thereby to provide an evidence-base
from which vaccine regimens might be fur-
ther optimized to protect against target
pathogens, while promoting potential for
heterologous benefits where possible. The
other gap lies in the knowledge needed to
design a harmonized program of maternal
and infant immunization to protect new-
borns and young infants from diseases in
addition to tetanus, such that protective
antibodies acquired by the infant through
immunization of the mother do not unduly
impede the responses of the infant to those
vaccines.
Beginning with the pioneering studies
by Mackeness in the 1960s, an extensive
body of research from mouse and other
model systems has shown that immuniza-
tion with BCG, infection with heterolo-
gous pathogens, and exposure to microbial
products can “non-specifically” increase,
and in other contexts decrease, host resis-
tance to other infectious agents, cancer, and
autoimmunity (1–3). Similarly, the impact
of antibodies acquired from the mother
on postnatal immunization of their infants
has been evaluated in model systems, as
reviewed in this series by Niewisk (4). This
information provides supporting biologi-
cal rationale and illustrates principles that
are likely relevant to humans. Herein, the
focus is on human evidence and evidence
gaps, which if addressed would illumi-
nate the degree to which those principles
apply to human infants and inform ways
be which they might be translated into
appropriate action.
HETEROLOGOUS EFFECTS OF VACCINES
The immune system is designed to con-
tinuously monitor environmental context.
On association with the microbial world
during and after parturition, both the
innate and adaptive immune systems must
rapidly learn from and establish benefi-
cial equipoise with their new microbe-rich
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world. Whereas, it was previously thought
that learning took place only within the
adaptive (antigen-specific) immune sys-
tem, early clues, and a wealth of more
recent data indicate that the innate immune
response can also be trained to respond dif-
ferently on subsequent encounters, though
likely without the extended durability of
immune memory characteristic of long-
lived,adaptive immune responses. As noted
by MacGillivray and Kollmann (5) and
described in additional detail in other pub-
lications (6–8), such “trained” immunity
and its potential impact on health out-
comes appear to have been hiding in plain
sight for some time in the form of non-
specific or heterologous effects of microbial
exposure or immunization on near-term
risk of death – apparently death caused by
infections other than those in the“training”
microbes or vaccines.
An increasing body of ecological evi-
dence supports the notion that live vac-
cines, most notably BCG and measles
vaccines, reduce risk of near-term death,
whereas no such benefit and potentially
increased risk have been ascribed to inacti-
vated vaccines, such as DTP (6). Consistent
with the less durable nature of “trained”
innate immunity, extant evidence suggests
that the most recently received vaccine is
deterministic – if a live vaccine, risk is
decreased, if inactivated, risk is increased
in the following months. In addition to
this ecological record, a composite analy-
sis of two randomized controlled trials
of low birth weight infants in Guinea-
Bissau in which BCG was given at birth or
delayed until a later age revealed that birth
administration was associated with a 58,
48, and 21% reduction in infant mortality,
respectively, in the first days, month, and
year of life, apparently related to reduced
rates of sepsis and respiratory illness (6).
MacGillivray and Kollman (5) also refer to
a report from Australia indicating that BCG
given at birth may enhance the immune
response to routine immunizations during
the first 6 months of life. However, only
the quantity of antibody to two pneumo-
coccal serotype was significantly greater in
those given BCG at birth. And there was
an inconsistency in this study compared to
a previous one from the Gambia, in that
the antibody response to the birth dose of
hepatitis B vaccine was lower in those given
concurrent BCG in Australia and higher in
the Gambia (9). That said, there is con-
siderable biological plausibility that immu-
nization, like other environmental expo-
sures, can have heterologous effects on the
immune response in ways that affect clini-
cal outcomes. For example, it was recently
reported that priming through TLR5 by
flagellin on gut commensal bacteria is an
important factor in the ability of mice to
generate robust immune responses to a
parenterally administered viral (influenza)
vaccine (10).
Biological plausibility and the body of
largely ecological evidence notwithstand-
ing, more rigorous controlled human trials
and contemporary analytical approaches
to probe the underlying biological mech-
anisms for the benefits, risks, or lack of
heterologous effects of vaccines are needed.
The most striking apparent heterologous
benefit of BCG and measles vaccination
is reduction in mortality, yet for the most
part, the causes of that mortality are wholly
or at best partly cryptic. New approaches
to employ minimally invasive autopsies in
which small samples are fully analyzed to
detect known pathogens, unknown, and
unculturable potential pathogens or patho-
bionts and in parallel to assess the human
immune response in molecular detail and
at single cell resolution may illuminate
causes and inform more appropriately tar-
geted next steps. The import of such studies
goes far beyond academic interest, because
such information is needed to provide a
mechanism-based rationale for the clini-
cal evaluation and optimization of vaccine
administration schedules.
TOWARD A HARMONIZED MATERNAL
AND INFANT IMMUNIZATION
PROGRAM
While heterologous immunity from a birth
dose of BCG may provide a broad mea-
sure of protection for the first weeks
to months of life, a complementary and
more targeted approach is immunization
of the pregnant woman to induce anti-
bodies and thereby passively immunize her
as yet unborn infant, as highlighted in
the review by Niewisk (4). This approach
has only been practiced widely for pre-
vention of neonatal tetanus. But more
recently, administration of combination of
tetanus, diphtheria, and acellular pertussis
vaccine boosters has led to the reduction
of infant deaths due to pertussis in the
United Kingdom [reviewed in Ref. (11)].
This approach has been implemented in
other developed countries but not yet in
resource-limited settings due in part to the
higher cost and less durable immunity pro-
vided by acellular compared to whole cell
pertussis vaccines. The observation that
pregnant women were a highly vulnera-
ble population during the recent H1N1
influenza pandemic, prompted broader
implementation of maternal influenza vac-
cination. The value of this approach to
protect both the mother and her new-
born infant was demonstrated recently in
South Africa – maternal immunization
resulted in efficient transplacental trans-
fer of influenza antibodies and reduced the
rate of confirmed influenza illness in the
infant by approximately half; this reduc-
tion appeared to reflect both direct pro-
tection of infants by the passively derived
antibody and reduced risk for infection of
the mother and subsequent transmission to
her infant (12).
These successes and the absence of
major vaccine-attributable adverse events
have created momentum to more broadly
implement maternal immunization to
protect infants in the first 3–4 months
of life before immunization of the
infant would provide protection. Vac-
cines for respiratory syncytial virus (RSV),
cytomegalovirus (CMV), and the group B
streptococcus (GBS), which are all under
active development, would when available
logically be included in maternal immu-
nization programs. In the case of CMV and
GBS, where death and disability are largely
restricted to infection acquired in utero
or the first 3 months of life, respectively,
maternal immunization without infant
immunization is all that would be required.
There is a potential caveat regarding
the benefits of maternal immunization –
inhibition by passively acquired maternal
antibodies of the infant’s immune response
to active immunization with homolo-
gous vaccines [reviewed in Ref. (4, 13)].
This inhibition has been clearly demon-
strated in the context of measles immu-
nization – maternally derived antibody
appears to impede the infant’s antibody but
not T cell responses. Despite the inhibi-
tion of antibody production, B cell priming
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appears to occur in the infant, which
allows high-affinity, protective anamnes-
tic antibody responses to booster measles
immunization given at a later age (13), even
though the final antibody concentrations
may be somewhat lower (14).
What is the mechanism for the
inhibitory effect of maternal antibody?
Niewisk (4) makes a strong case that the
dominant mechanism is inhibitory sig-
naling through FcγRIIb. This conclusion
is consistent with the retention of T cell
responses and a wealth of experimental evi-
dence on Fcγ receptor and B cell biology
(15). Because FcγRIIb-mediated inhibition
of B cell responses is a general mecha-
nism, which in the absence of passive anti-
body serves both as a rheostat to prevent
excessive antibody production and to fos-
ter affinity maturation (15), interference
by passively acquired antibodies should
be a universal phenomenon for all vac-
cines. Evidence cited by Niewisk (4) sug-
gests that this is true though the degree
and consistency of inhibition observed in
humans varies between vaccines and stud-
ies (11, 13). This lack of consistency and the
paucity of direct mechanistic evidence in
humans impede implementation of a ratio-
nal, harmonized, passive maternal, and
active infant immunization program.
Until recently, the technologies and
cross-disciplinary scientific cooperation
needed to provide such evidence were lack-
ing. However, technology is now in hand
to analyze the human antibody, B and
plasma cells and associated T helper cell
repertoires, and responses on small vol-
umes of blood and thereby to trace over
time the evolutionary pathways of human
infant immune responses to vaccines at sin-
gle cell, molecular, and structural levels.
Such studies have illuminated the pathways
by which broadly neutralizing antibodies
are induced in HIV-infected individuals
(16, 17) and led to the identification of
antibodies that can neutralize both RSV
and the related human metapneumovirus
(18). Elucidation of the structure of the
RSV F protein in complex with these and
other neutralizing monoclonal antibodies
has led to the structure based-design of
recombinant F protein vaccines stabilized
or scaffolded in a pre-fusion confirmation,
which induce protective antibodies in non-
human primates (19, 20). Such informa-
tion could be used to design different RSV
vaccines for maternal immunization and
infant immunization (e.g., one in a pre-
fusion and another in a post-fusion confir-
mation), such that vaccine-induced mater-
nally derived antibodies would not bind
to and inhibit the antibody response to
the infant vaccine. Alternatively, advances
in monoclonal antibody isolation, in engi-
neering of antibodies to enhance dura-
tion and potency, and in manufacturing
technologies to reduce production costs
might together be harnessed to produce
monoclonal antibodies by which to pas-
sively protect newborn infants [e.g., for
RSV or RSV and metapneumovirus (18)],
and thereby eliminate the need to immu-
nize the mother. In either scenario, the later
need to actively immunize the infant and
potential inhibition by passively derived
antibodies must be addressed (unless the
duration of passive protection is sufficient
to encompass the period of risk, as for
GBS). In addition to the possible engi-
neering of infant immunogens that are
not engaged by passively derived antibod-
ies as described above for RSV, vaccine
antigen content and formulation may be
optimized through the use of adjuvants
that more effectively yet safely promote
antibody responses in young infants, as
was shown for the MF59-adjuvanted H1N1
vaccine (21), which may allow inhibitory
effects of maternal antibodies to be over-
come (4); this optimization may be use-
fully informed by a more comprehensive
knowledge of the infant’s age-dependent
innate immune responses (5, 22). Such
approaches, and the translational and clin-
ical research programs needed to evaluate
them, could form the basis for a more
evidence-based approach to vaccine design,
formulation, and immunization schedules
for mother and infant.
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